
Yasuyuki Ishii

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7168439/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chimerism through the activation of invariant natural killer T cells prolongs graft survival after transplantation of induced pluripotent stem cell–derived allogeneic cardiomyocytes. PLoS ONE, 2022, 17, e0264317.	2.5	0
2	Donor Treg expansion by liposomal αâ€galactosylceramide modulates Tfh cells and prevents sclerodermatous chronic graftâ€versusâ€host disease. Immunity, Inflammation and Disease, 2021, 9, 721-733.	2.7	3
3	A Novel Liposome Formulation Carrying Both an Insulin Peptide and a Ligand for Invariant Natural Killer T Cells Induces Accumulation of Regulatory T Cells to Islets in Nonobese Diabetic Mice. Journal of Diabetes Research, 2019, 2019, 1-9.	2.3	3
4	Impact of activated invariant natural killer T cells on the expansion of regulatory T cell precursors in murine thymocytes in vitro. Immunology Letters, 2019, 206, 41-48.	2.5	2
5	Increased Foxp3 + Helios + Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biology of Blood and Marrow Transplantation, 2017, 23, 625-634.	2.0	59
6	Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without Abrogating the Graft-versus-Leukemia Effect in Murine Models. Biology of Blood and Marrow Transplantation, 2011, 17, 1154-1168.	2.0	46
7	Characterization of the immature dendritic cells and cytotoxic cells both expanded after activation of invariant NKT cells with α-galactosylceramide in vivo. Biochemical and Biophysical Research Communications, 2008, 369, 485-492.	2.1	18
8	Alpha-galactosylceramide-driven immunotherapy for allergy. Frontiers in Bioscience - Landmark, 2008, Volume, 6214.	3.0	32